Keyphrases
Cutaneous T-cell Lymphoma
100%
Retreatment
100%
Denileukin Diftitox
100%
Adverse Events
16%
Overall Response Rate
16%
Clinically Significant
16%
Nausea
16%
Median Progression-free Survival
16%
First Year
16%
Stage IA2
16%
Partial Response
16%
Phase II Trial
16%
Duration of Response
16%
Placebo-controlled Trial
16%
Upper Respiratory Tract Infection
16%
Intent-to-treat
16%
Relapsed Patients
16%
Nursing and Health Professions
Retreatment
100%
Cutaneous T Cell Lymphoma
100%
Denileukin Diftitox
100%
Efficacy
100%
Adverse Event
16%
Progression Free Survival
16%
Nausea
16%
Placebo
16%
Rigor
16%
Intention to Treat Analysis
16%
Upper Respiratory Tract Infection
16%
Isoprenaline
16%
Medicine and Dentistry
Cutaneous T Cell Lymphoma
100%
Retreatment
100%
Denileukin Diftitox
100%
Nausea
16%
Adverse Event
16%
Progression Free Survival
16%
Placebo
16%
Intention-to-Treat Analysis
16%
Rigor
16%
Isoprenaline
16%
Upper Respiratory Tract Infection
16%
Phase III Trials
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cutaneous T Cell Lymphoma
100%
Denileukin Diftitox
100%
Placebo
16%
Progression Free Survival
16%
Nausea
16%
Adverse Event
16%
Isoprenaline
16%
Upper Respiratory Tract Infection
16%
Rigor
16%
Phase III Trials
16%